-
FIRMAGON® has a significantly greater probability of PSA recurrence-free survival than leuprolide in prostate cancer patients
-Results from a phase III pivotal study sub-analyses reported in European Urology show that…
0 -
Launch of FIRMAGON
-Launch of FIRMAGON® (degarelix), a GnRH blocker for advanced hormone-dependent prostate cancer.
-
Ferring donates $3 million to the Royal Textile Academy of Bhutan
-Frederik Paulsen, Chairman, Ferring Pharmaceuticals, announced a $3 million donation to the Royal Textile Academy of Bhutan…
-
Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) 2010 Theme Announced
-Ferring Pharmaceuticals is proud to announce the second Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) today…
-
New Data Supports Significant Economic and Clinical Value of MENOPUR® in IVF
-New data from an economic analysis presented today at this year’s European Society of Human Reproduction and Embryology (ESHRE) congress showed that…
-
Ferring launches New International Fertility Media Award (FIMA) 2010
-Ferring is proud to announce the launch of its first Fertility Media Award (FIMA) today during the 25th Annual Society of Human Reproduction and Embryology (ESHRE) congress…
-
Ferring Pharmaceuticals announces new Board Member
-Ferring Pharmaceuticals announced today that Dr. John Patterson CBE FRCP has been appointed as a new Board Member with immediate effect…
-
Frost & Sullivan Accolade for Ferring Pharmaceuticals
-The 2008 Frost & Sullivan European Human Growth Hormone Competitive Strategy Leadership Award is presented to Ferring Pharmaceuticals…
-
FIRMAGON® (degarelix) is launched in Europe for the treatment of advanced prostate cancer
-Today marks the European launch of FIRMAGON® (degarelix), a new treatment option in hormonal therapy for prostate cancer…
-
Ferring Pharmaceuticals creates Executive Board
-Today, Ferring Pharmaceuticals announced the creation of a new Executive Board…
Archive for 2009
2009